source
- STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatmentProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to something.
- FDA warns investors that advisory panel reviews do not guarantee drug approval, cites concerns at Capricor and ReplimuneThe FDA issued a reminder to investors that the outcomes of advisory committee meetings are not final decisions on a drug’s fate. This week the agency released briefing documents highlighting conc…